PolyU-nurtured biopharmaceutical start-up ABRAM accepted by Roche Accelerator

The Hong Kong Polytechnic University (PolyU) celebrates the acceptance of ABRAM Therapeutics Limited (ABRAM), a start-up co-founded by a PolyU scholar, into the Roche Accelerator. This marks the first time a Hong Kong-based start-up being welcomed by this prestigious innovation hub. Nurtured within the PolyVentures start-up ecosystem, ABRAM focuses on its ground-breaking drug candidate, ABarginase, for treating obesity and related metabolic disorders such as diabetes and fatty liver disease. This milestone will significantly advance the development of the drug, paving the way for its clinical application to benefit patients worldwide.

The start-up was co-founded by Prof. Thomas LEUNG Yun-chung, Professor of the PolyU Department of Applied Biology and Chemical Technology, Lo Ka Chung Charitable Foundation Professor in Pharmaceutical Sciences, and Director of University Research Facility in Life Sciences, along with Prof. Alisa SHUM Sau-wun, Associate Professor of the School of Biomedical Sciences of the Faculty of Medicine of The Chinese University of Hong Kong (CUHK) to further develop and commercialise ABarginase, the breakthrough outcome of their joint research project.

ABarginase is the result of innovative drug design and advanced protein engineering. Employing a long-acting formulation to provide sustained therapeutic effects, this next-generation recombinant human arginase offers enhanced efficacy with reduced dosing frequency. Preclinical data demonstrates ABarginase’s remarkable potential to promote substantial weight loss, restore healthy body composition, reverse insulin resistance, and alleviate inflammation. These properties address the underlying causes of obesity-related chronic diseases, heralding a transformative approach to the effective treatment of metabolic diseases. ABarginase has been awarded the International Federation of Inventors’ Associations Best Invention Award and a Gold Medal with Congratulations of the Jury at the 48th International Exhibition of Invention Geneva.

Roche, one of the world’s largest biotech companies and the global leader in in-vitro diagnostics, pursues scientific excellence to discover and develop transformative and innovative solutions across major disease areas. Roche is a global pioneer in pharmaceuticals with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology, neurology and cardiovascular, renal and metabolism. As Roche’s first in-house accelerator globally, the Roche Accelerator provides tailor-made support for member start-ups in pharma, diagnostics, personalised healthcare, and digital and AI-driven healthcare. With “disruptive innovation” as a key selection criterion, Roche Accelerator accepts fewer than 5% of its applicants. By joining Roche Accelerator, ABRAM gains access to Roche’s extensive expertise and resources, which will expedite the clinical development of ABarginase, facilitating the translation of this cutting-edge therapy from laboratory research to clinical application.

Prof. Leung said, “Joining this distinguished innovation ecosystem as the first Hong Kong-based start-up is a significant honour for our team and a testament to the collaborative research efforts between PolyU and CUHK. We believe that the strategic collaboration between Roche and ABRAM, along with the resources of a multinational pharmaceutical company and Hong Kong’s strengths in basic scientific research, will accelerate the clinical translation of ABarginase.”

Prof. Shum added, “Our mission aligns seamlessly with Roche’s vision of ‘doing now what patients need next’. With the mentorship and resources provided by the Roche Accelerator, we are better positioned to make ABarginase available to millions of patients struggling with obesity.”

Prof. Christopher Chao, PolyU Vice President (Research and Innovation), congratulated ABRAM, stating, “ABRAM’s achievement validates our efforts in empowering researchers and start-ups in translating research discoveries into impactful real-world solutions. It exemplifies how cross-institutional collaborations can lead to the birth of game-changing biopharmaceutical technologies. We look forward to seeing ABarginase make a positive impact on global healthcare and will continue to support PolyU start-ups in their pursuit of innovation, enabling more life-saving and life-enhancing technologies to reach the market and benefit humanity.”

PolyU is committed to fostering innovation and entrepreneurship, nurturing the next-generation of entrepreneurs eager to tackle societal challenges with innovative solutions. Through PolyVentures, PolyU supports its start-ups at every stage of their entrepreneurial journeys – from education and ideation to incubation, acceleration, and fundraising. To date, it has nurtured over 500 start-ups, including four unicorns.

***END***